Context Therapeutics (NASDAQ:CNTX – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.01, reports.
Context Therapeutics Stock Up 5.8 %
Shares of CNTX traded up $0.04 during trading hours on Friday, reaching $0.82. 19,238 shares of the company traded hands, compared to its average volume of 387,490. The stock has a market capitalization of $61.12 million, a PE ratio of -0.90 and a beta of 2.06. Context Therapeutics has a fifty-two week low of $0.64 and a fifty-two week high of $2.75. The stock has a fifty day simple moving average of $0.86 and a 200 day simple moving average of $1.45.
Analysts Set New Price Targets
CNTX has been the subject of several research analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price objective on shares of Context Therapeutics in a research report on Friday. Citizens Jmp upgraded Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. JMP Securities initiated coverage on Context Therapeutics in a research report on Wednesday, January 8th. They issued an “outperform” rating and a $4.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Context Therapeutics in a research report on Friday. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $6.17.
Context Therapeutics Company Profile
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
See Also
- Five stocks we like better than Context Therapeutics
- How to Invest in Blue Chip Stocks
- Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets
- There Are Different Types of Stock To Invest In
- Cybersecurity Stocks Surge as $32B Deal Reshapes the Industry
- How to trade using analyst ratings
- Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
